jCyte Presents Results of Clinical Testing in Retinitis Pigmentosa
December 14, 2017 – Cell therapy company jCyte has announced results from a phase 1/2a clinical trial for its investigational product, jCell, in retinitis pigmentosa […]
News
Where Our Retinitis Pigmentosa Therapy is Right Now
In the past few months, jCyte has made a number of important announcements. In December, we received an $8.3 million grant from the California Institute […]
jCyte Receives Regenerative Medicine Advanced Therapy Designation
May 2, 2017 – Cell therapy company jCyte announced that the U.S. Food & Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for […]
Powered by CIRM Grant, jCyte Launches New Clinical Trial
Phase 2b study will investigate safety and efficacy of retinitis pigmentosa therapy April 19, 2017 – Cell therapy company jCyte is launching a phase […]
Retinitis Pigmentosa Therapy Highlighted at CIRM Symposium
The California Institute for Regenerative Medcine’s (CIRM’s) second annual Alpha Stem Cell Clinics Network symposium showcased how stem cell therapies are rapidly moving towards the […]
CIRM Grant Sets Stage for Next Clinical Trial
Developing groundbreaking therapies can be maddeningly slow, but jCyte recently took a big step forward, receiving an $8.3 million grant from the California Institute for […]
Working Towards an RP Treatment
Recently, the Gavin Herbert Eye Institute at UC Irvine profiled jCyte co-founder Jing Yang, MD, PhD, and retinitis pigmentosa trial participant Elaine Cain. The article highlights Dr. […]
jCyte Completes Enrollment for Phase 1/2a Safety Trial
November 28, 2016 – California-based regenerative medicine company jCyte has completed enrollment in a phase 1/2a trial to study the safety of its stem cell therapy candidate […]
Dr. Henry Klassen: Light at the End of the Tunnel
Dr. Henry Klassen has spent decades working on a therapy for retinitis pigmentosa. In this recent Tedx presentation, Dr. Klassen recounts some of the ups […]
Preliminary Safety Results Highlighted in Optometry Today
British website and journal Optometry Today recently published an article about the preliminary safety results from jCyte’s ongoing retinitis pigmentosa trial. The piece discussed the treatment’s safety […]